Anavex Life Sciences Corp (AVXL)

[wildcard235]

Beta-secretase (BACE) inhibitors only target amyloid-beta misfolding, ignoring tau and other issues, according to my notes. As the article points out, Eli Lilly dropped a BACE inhibitor due to possible liver damage during their trials. If I am correct that BACE inhibitors only target a-beta, they are still ignoring the fact that many Azheimer's patients have no appreciable a-b plaques and are ignoring a statement from the FDA which basically said, "Hey, big pharma, attacking amyloid-beta doesn't work. Try something else."